Analysis on the influencing factors of the incidence and remission of non-alcoholic fatty liver disease in Binhai County

doi:10.3877/cma.j.issn.2095-2015.2023.05.016

Abstract

Abstract:

Objective

To explore the incidence and remission of non-alcoholic fatty liver disease (NAFLD) in Binhai County, Jiangsu Province, and its influencing factors.

Methods

The 5 916 people who underwent health examinations both in 2017 and 2019 were participated in the study, and the biochemical indicators results and liver color Doppler ultrasound results were collected.

Results

The two-year cumulative incidence of NAFLD in the baseline population without fatty liver disease was 15.47%, and the two-year cumulative remission rate of baseline NAFLD patients was 29.64%. The incidence in males (20.18%) was higher than that in females (12.91%), with a statistically significant difference (P<0.001). The remission rate of females (32.27%) was higher than that of males (27.97%), with a statistically significant difference (P=0.010). With the increase of age, the incidence of NAFLD increased (P<0.001), but the remission rate didn′t change (P=0.81). The incidence of NAFLD increased (P<0.001) and the remission rate decreased (P<0.001) with increasing body mass index (BMI). Abnormal baseline BMI, total cholesterol, triglyceride and other indicators were risk factors of the NAFLD; while blood pressure and BMI were independent influencing factors for the remission of NAFLD.

Conclusion

BMI is an important influencing factor for the incidence and remission of NAFLD, suggesting that weight control is an effective measure to reduce the incidence of NAFLD and increase the regression rate.

Key words: Non-alcoholic fatter liver disease, Incidence rate, Remission rate, Body mass index

Yunlin Li, Donghua Lou. Analysis on the influencing factors of the incidence and remission of non-alcoholic fatty liver disease in Binhai County[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 354-358.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2023.05.016

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2023/V13/I05/354

Figures/Tables 5

References 20

1	GE X，Zheng L，Wang M，et al.Prevalence trends in non-alcoholic fatty liver disease at the global，regional and national levels，1990–2017：a population-based observational study[J]．BMJ Open，2020，10(8)：e036663.
2	Harrison SA，Gawrieh S，Roberts K，et al.Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort[J]．J Hepatol，2021，75(2)：284-291.
3	Deǎertekin B，Tozun N，Demir F，et al.The Changing Prevalence of Non-Alcoholic Fatty Liver Disease(NAFLD)in Turkey in the Last Decade[J]．Turk J Gastroenterol，2021，32(3)：302-312.
4	Wu Y，Zheng Q，Zou B，et al.The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product：a meta-analysis[J]．Hepatol Int，2020，14(2)：259-269.
5	中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会．非酒精性脂肪性肝病防治指南(2018年更新版)[J]．临床肝胆病杂志，2018，34(5)：947-957.
6	中国成人血脂异常防治指南制订联合委员会．中国成人血脂异常防治指南(2016年修订版)[J]．中华心血管病杂志，2016，31(10)：937-953.
7	Decker RD，Ghiraldi EM，Weiss AH，et al.Nonalcoholic Fatty Liver Disease Is an Independent Risk Factor for Nephrolithiasis in Women：Findings from NHANES III[J]．J Endourol，2020，34(12)：1258-1262.
8	何帆，黎文军，马觉民．柳州市健康体检人群糖脂代谢，体质量指数异常与脂肪肝发病率的关系[J]．贵州医药，2018，42(9)：1129-1131.
9	余纪会，唐兰，赵文苹，等．重庆地区体检人群脂肪肝与其他常见代谢性疾病患病情况及相关性分析[J]．公共卫生与预防医学，2019，30(3)：87-90.
10	余双彬，俞梦璐，陈曦，等．四川省绵阳市成人脂肪肝流行现况及其代谢异常情况分析[J]．中国医学科学院学报，2019，41(3)：323-330.
11	王珊，张健，张卫欢，等．体质量指数联合腰围对2型糖尿病患者新发非酒精性脂肪肝的预测价值[J]．南方医科大学学报，2019，39(11)：1293-1297.
12	王珊，张健，张杰，等．体质量指数轨迹与新发非酒精性脂肪性肝病相关性的队列研究[J]．中华肝脏病杂志，2020，28(7)：597-602.
13	刘怀磊，龚卫红．老年人BMI变化对非酒精性脂肪性肝病发病的影响研究[J]．中国初级卫生保健，2020，34(9)：72-74.
14	Xing J，Guan X，Zhang Q，et al.Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease：A Population-Based Study[J]．Obesity Facts，2021，14(2)：190-196.
15	Kim MN，Lo CH，Corey KE，et al.Weight gain during early adulthood，trajectory of body shape and the risk of nonalcoholic fatty liver disease：A prospective cohort study among women[J]．Metabolism，2020，113：154398.
16	周琦，范建高，陈源文，等．上海宝钢职工非酒精性脂肪性肝病消退率及其影响因素研究[J]．中国实用内科杂志，2011，31(12)：934-937.
17	Lin YC，Chang PF，Liu K，et al.Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents[J]．J Formos Med Assoc，2021，121(1P1)：36-42.
18	Zhou Q，Wang Y，Wang J，et al.Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]．Medicine，2021，100(10)：e24940.
19	Targher G，Corey KE，Byrne CD，et al.The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments[J]．Nat Rev Gastroenterol Hepatol，2021，18(9)：599-612.
20	韩洁．非酒精性脂肪肝患病率调查、危险因素分析及与动脉硬化关系的临床研究[D]．济南：山东大学，2019.

变量		基线无NAFLD例数	发病例数	发病率(%)	基线有NAFLD例数	消退例数	消退率(%)
性别
	男性	1214	245	20.18^a	833	223	27.97^b
	女性	2238	289	12.91	911	294	32.27
年龄
	≤30岁	230	16	6.96^c	49	14	28.57^d
	31~40岁	607	64	10.54	190	55	28.95
	41~50岁	1044	155	14.85	462	147	31.82
	51~60岁	771	148	19.20	500	135	27.00
	61~70岁	579	111	19.17	413	121	29.30
	≥71岁	221	40	18.10	130	45	34.62

变量		基线无NAFLD例数	发病例数	发病率(%)	基线有NAFLD例数	消退例数	消退率(%)
性别
	男性	1214	245	20.18^a	833	223	27.97^b
	女性	2238	289	12.91	911	294	32.27
年龄
	≤30岁	230	16	6.96^c	49	14	28.57^d
	31~40岁	607	64	10.54	190	55	28.95
	41~50岁	1044	155	14.85	462	147	31.82
	51~60岁	771	148	19.20	500	135	27.00
	61~70岁	579	111	19.17	413	121	29.30
	≥71岁	221	40	18.10	130	45	34.62

组别	例数	收缩压(mmHg)	舒张压(mmHg)	BMI(kg/m²)	ALT(U/L)	AST(U/L)	TC(mmol/L)	TG(mmol/L)	FBG(mmol/L)	Cr(μmol/L)	TBil(μmol/L)
NAFLD新发情况比较
NAFLD新发组	534	140.26±21.10	84.33±11.57	26.19±2.81	26.00±16.69	21.42±8.83	4.78±0.89	1.68±1.16	5.41±1.16	61.24±15.63	13.19±5.33
无NAFLD组	2918	131.58±20.79	79.42±10.99	23.50±2.68	21.51±16.32	22.58±10.52	4.59±0.89	1.68±1.16	5.13±1.13	58.04±14.70	13.53±5.41
统计值		8.76	9.08	20.49	5.82	2.69	4.41	11.68	5.40	4.57	1.36
P		<0.001	<0.001	<0.001	<0.001	0.01	<0.001	<0.001	<0.001	<0.001	0.17
NAFLD消退情况比较
NAFLD消退组	517	140.86±20.50	84.39±10.76	26.44±2.68	30.41±22.64	23.99±12.59	4.95±0.99	1.94±1.24	5.77±1.72	60.28±15.53	13.57±5.41
NAFLD持续组	1228	144.40±20.80	86.61±11.03	29.99±7.54	35.89±22.93	26.03±12.29	4.99±0.91	2.34±1.65	6.05±1.74	61.11±14.75	14.20±5.48
统计值		3.28	3.9	10.43	4.58	3.14	0.913	5.03	3.05	1.03	2.24
P		<0.001	<0.001	<0.001	<0.001	<0.001	0.36	<0.001	<0.001	0.29	0.03

组别	例数	收缩压(mmHg)	舒张压(mmHg)	BMI(kg/m²)	ALT(U/L)	AST(U/L)	TC(mmol/L)	TG(mmol/L)	FBG(mmol/L)	Cr(μmol/L)	TBil(μmol/L)
NAFLD新发情况比较
NAFLD新发组	534	140.26±21.10	84.33±11.57	26.19±2.81	26.00±16.69	21.42±8.83	4.78±0.89	1.68±1.16	5.41±1.16	61.24±15.63	13.19±5.33
无NAFLD组	2918	131.58±20.79	79.42±10.99	23.50±2.68	21.51±16.32	22.58±10.52	4.59±0.89	1.68±1.16	5.13±1.13	58.04±14.70	13.53±5.41
统计值		8.76	9.08	20.49	5.82	2.69	4.41	11.68	5.40	4.57	1.36
P		<0.001	<0.001	<0.001	<0.001	0.01	<0.001	<0.001	<0.001	<0.001	0.17
NAFLD消退情况比较
NAFLD消退组	517	140.86±20.50	84.39±10.76	26.44±2.68	30.41±22.64	23.99±12.59	4.95±0.99	1.94±1.24	5.77±1.72	60.28±15.53	13.57±5.41
NAFLD持续组	1228	144.40±20.80	86.61±11.03	29.99±7.54	35.89±22.93	26.03±12.29	4.99±0.91	2.34±1.65	6.05±1.74	61.11±14.75	14.20±5.48
统计值		3.28	3.9	10.43	4.58	3.14	0.913	5.03	3.05	1.03	2.24
P		<0.001	<0.001	<0.001	<0.001	<0.001	0.36	<0.001	<0.001	0.29	0.03

基线BMI	NAFLD发病^a					NAFLD消退^b
基线BMI	例数	发病数(例)	发病率(%)	χ²	P	例数	消退数(例)	消退率(%)	χ²	P
正常组				16.25	<0.001				1.168	0.28
BMI差值≤0	564	14	2.48			34	18	52.94
BMI差值>0	697	53	7.60			120	51	42.50
小计^※	1261	67	5.31			154	69	44.81
超重组				66.31	<0.001				6.726	0.01
BMI差值≤0	933	87	9.32			287	111	38.68
BMI差值>0	341	93	27.27			243	68	27.98
小计^※	1274	180	14.13			530	179	33.77
肥胖组				14.87	<0.001				13.491	<0.001
BMI差值≤0	855	254	29.07			945	256	27.08
BMI差值>0	62	33	53.23			115	13	11.30
小计^※	917	287	31.30			1060	269	25.37

Please choose a citation manager

Content to export